Ever since the Supreme Court struck down Myriad Genetics' patent claims on isolated BRCA1 and BRCA2 gene sequences, industry observers have breathlessly speculated whether the company would take legal action against labs challenging its decades-long reign over the BRCA genetic testing market.

Myriad made its move this week. Along with several other assignees to a handful of US patents underlying the BRACAnalysis test, Myriad filed a patent infringement lawsuit against Ambry Genetics and Gene by Gene.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.

New Mexico is re-doing its proposed science education standards after criticism, the Associated Press reports.

La Trobe University's Jenny Graves has won the $250,000 Prime Minister's Prize for Science, the Guardian reports.

Agbio executives say gene editing will speed up breeding efforts, according to the Wall Street Journal.